Skip to main content
Equibles
PRLD logo

PRLD · Prelude Therapeutics Inc · Webcasts, Transcripts & Audio

Track PRLD — free

Use PRLD with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PRLD.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$3.78 +0.11 (+3.00%)
Russell 2000 member Rebalance outlook locked
Market Cap
$309.24M
Shares
79.80M
Volume · Oct 5 206.3K Avg daily vol (3M) 472.8K

Prelude Therapeutics Inc Webcasts

Earnings calls, investor updates, investor days and conferences for Prelude Therapeutics Inc (PRLD), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
· $3.00M −$32.27M '24 Q3 24-12-02 · $ −$32.09M '25 Q1 25-05-06 ▲116.7% $6.50M −$19.73M '25 Q3 25-11-12 LATEST · $5.64M −$16.46M '25 Q4 26-03-10
Conference
Investor event
2026-09-16
Prelude Therapeutics Inc (PRLD) September 2026 Conference
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-06-10
Prelude Therapeutics Inc (PRLD) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-06-03
Prelude Therapeutics Inc (PRLD) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q4
2026-03-10
Prelude Therapeutics Inc (PRLD) Q4 2025 Earnings Call
Revenue
$5.64M*
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-12
Prelude Therapeutics Inc (PRLD) Q3 2025 Earnings Call Transcript
Positive tone CAP-6A selective degrader program JAK2V617F selective inhibitor program Clinical development timing / regulatory risk
Revenue
$6.50M
▲ 116.7% YoY
Diluted EPS
$-0.26
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-06
Prelude Therapeutics Inc (PRLD) Q1 2025 Earnings Call
Revenue
$
Diluted EPS
$-0.42
Rev · 2q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-10
Prelude Therapeutics Inc (PRLD) Q4 2024 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-12-02
Prelude Therapeutics Inc (PRLD) Q3 2024 Earnings Call
Revenue
$3.00M
Diluted EPS
$-0.43
Audio Transcript Slides 8-K10-Q
Showing 1–8 of 8 webcasts
Key facts CIK 1678660 CUSIP 74065P101 13F (30d) 1 filings 1 filers Visit website Investor relations